NextCell Pharma AB (OM: NXTCL)
Health Care · Biotechnology · SE
Skr1.00
-3.85% today · +9.6% 1Y
NextCell Pharma AB (OM: NXTCL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $13.10M and employs 24 people.
Over the last twelve months the share price has gained 9.6%, trading between 0.63 and 1.78.
Tweenvest scores NextCell Pharma AB across four factors: quality 36/100, value 60/100, growth 98/100. Its strongest factor is growth.
NXTCL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $13.10M
- Revenue (TTM)
- $1.11M
- P/E
- —
- EPS
- -0.33
- Dividend yield
- —
- Beta (5Y)
- 0.68
- 52-week high
- Skr1.78
- 52-week low
- Skr0.63
- Avg volume (3M)
- —
- Shares outstanding
- 126.39M
- Employees
- 24
- Next earnings
- —
About NextCell Pharma AB
NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an investigational drug derived from stem cells, primarily formulated to address autoimmune and inflammatory ailments. Beyond therapeutic development, NextCell Pharma AB also offers Cellaviva, a specialized stem cell banking service that enables families to securely preserve stem cells sourced from umbilical cord blood and tissue. Established in 2014, the company maintains its corporate headquarters in Huddinge, Sweden.
- ISIN
- SE0009723125
- Founded
- 2014
- Listed since
- Jul 13, 2017
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Tempest Therapeutics, Inc.NasdaqCM: TPST | $13.42M | $0.77 | -5.08% |
| Aelis Farma SAENXTPA: AELIS | $13.39M | €0.88 | -4.89% |
| Passage Bio, Inc.NasdaqCM: PASG | $13.26M | $3.78 | -8.25% |
| Lisata Therapeutics, Inc.NasdaqCM: LSTA | $13.25M | $1.20 | -18.37% |
| Regentis Biomaterials Ltd.NYSEAM: RGNT | $12.99M | $1.70 | -8.11% |
| Patrys LimitedASX: PAB | $12.95M | AU$0.03 | +3.23% |
| TME Pharma N.V.ENXTPA: ALTME | $12.85M | €0.12 | -6.01% |
| Xcell Therapeutics Inc.KOSDAQ: A373110 | $12.75M | ₩993.00 | -0.60% |
Figures last refreshed Oct 4, 2026.